{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T16:51:58Z","timestamp":1776185518207,"version":"3.50.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,2,5]],"date-time":"2022-02-05T00:00:00Z","timestamp":1644019200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,5]],"date-time":"2022-02-05T00:00:00Z","timestamp":1644019200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004328","name":"genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The extent to which different US private insurers require their enrollees to meet the same coverage criteria before gaining access to treatment is unclear. Our objective was to scrutinize the patient access criteria imposed by US private insurers for a set of rare neuromuscular disease (NMD) disease-modifying therapies (DMTs).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We examined coverage policies issued by 17 large US private insurers for the following NMD treatments: nusinersen and onasemnogene abeparvovec for spinal muscular atrophy, edaravone for amyotrophic lateral sclerosis, and eteplirsen for Duchenne muscular dystrophy. We reviewed the plans\u2019 coverage policies and identified the patient access criteria, including clinical prerequisites, step therapy protocols, and prescriber requirements. We compared the plans\u2019 patient access criteria with the therapies\u2019 US Food and Drug Administration (FDA)-labeled indications.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The included insurers issued 65 coverage policies for the included therapies. Plans imposed coverage restrictions beyond the FDA-approved indications in 60 coverage policies; plans did not cover eteplirsen in five policies. No therapy was covered the same way by all insurers. Plans applied clinical criteria beyond the FDA label indication in 56 policies and step therapy protocols in three policies. Plans required that a neurologist prescribe the therapy in 37 policies, 22 of which required the neurologist to have expertise in the particular disease. Plans often required patients to suffer from symptoms of particular severity; e.g. for eteplirsen, plans differed in their 6-min walk test requirements; for edaravone, some plans required that patients had normal respiratory function, while others required only that patients did not require ventilation; for nusinersen and onasemnogene abeparvovec, plans differed in the number of <jats:italic>SMN2<\/jats:italic> gene copies they required patients to have (<jats:italic>SMN2<\/jats:italic> copy number is correlated with disease severity).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The evaluated large US private insurers tended to impose coverage restrictions beyond the FDA label indication for the included set of rare NMD DMTs. Plans rarely applied the same patient access criteria in their coverage policies for the same products. Inconsistent coverage criteria mean that patients with different insurers have variable access to the same therapies across insurers.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13023-022-02182-3","type":"journal-article","created":{"date-parts":[[2022,2,5]],"date-time":"2022-02-05T11:02:42Z","timestamp":1644058962000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Patients\u2019 access to rare neuromuscular disease therapies varies across US private insurers"],"prefix":"10.1186","volume":"17","author":[{"given":"Nikoletta M.","family":"Margaretos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Komal","family":"Bawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalie J.","family":"Engmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5696-4894","authenticated-orcid":false,"given":"James D.","family":"Chambers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,2,5]]},"reference":[{"issue":"9","key":"2182_CR1","first-page":"589","volume":"6","author":"R Handfield","year":"2013","unstructured":"Handfield R, Feldstein J. Insurance companies\u2019 perspectives on the orphan drug pipeline. Am Health Drug Benefits. 2013;6(9):589\u201398.","journal-title":"Am Health Drug Benefits"},{"issue":"1","key":"2182_CR2","first-page":"15","volume":"3","author":"R Hyde","year":"2010","unstructured":"Hyde R, Dobrovolny D. Orphan drug pricing and payer management in the United States: are we approaching the tipping point? Am Health Drug Benefits. 2010;3(1):15\u201323.","journal-title":"Am Health Drug Benefits"},{"key":"2182_CR3","volume-title":"Which country has the world's best health care? Chapter 1: United States","author":"EJ Emanuel","year":"2020","unstructured":"Emanuel EJ. Which country has the world\u2019s best health care? Chapter 1: United States. Illustrated. New York: PublicAffairs; 2020.","edition":"Illustrated"},{"issue":"7","key":"2182_CR4","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1377\/hlthaff.2017.1553","volume":"37","author":"JD Chambers","year":"2018","unstructured":"Chambers JD, Kim DD, Pope EF, Graff JS, Wilkinson CL, Neumann PJ. Specialty drug coverage varies across commercial health plans in the US. Health Aff (Millwood). 2018;37(7):1041\u20137.","journal-title":"Health Aff (Millwood)"},{"issue":"10","key":"2182_CR5","first-page":"508","volume":"25","author":"JD Chambers","year":"2019","unstructured":"Chambers JD, Panzer AD, Kim DD, Margaretos NM, Neumann PJ. Variation in US private health plans\u2019 coverage of orphan drugs. Am J Manag Care. 2019;25(10):508\u201312.","journal-title":"Am J Manag Care"},{"issue":"9630","key":"2182_CR6","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.1016\/S0140-6736(08)60921-6","volume":"371","author":"MR Lunn","year":"2008","unstructured":"Lunn MR, Wang CH. Spinal muscular atrophy. Lancet. 2008;371(9630):2120\u201333.","journal-title":"Lancet"},{"key":"2182_CR7","unstructured":"SPINRAZA\u00ae (nusinersen). US prescribing information. Biogen Inc."},{"key":"2182_CR8","doi-asserted-by":"crossref","first-page":"175628561875445","DOI":"10.1177\/1756285618754459","volume":"11","author":"CD Wurster","year":"2018","unstructured":"Wurster CD, Ludolph AC. Nusinersen for spinal muscular atrophy. Ther Adv Neurol Disord. 2018;11:1756285618754459.","journal-title":"Ther Adv Neurol Disord"},{"key":"2182_CR9","unstructured":"ZOLGENSMA\u00ae (onasemnogene abeparvovec-xioi). US prescribing information. Novartis Gene Therapies, Inc."},{"issue":"22","key":"2182_CR10","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1056\/NEJM200105313442207","volume":"344","author":"LP Rowland","year":"2001","unstructured":"Rowland LP, Shneider NA. Amyotrophic lateral sclerosis. N Engl J Med. 2001;344(22):1688\u2013700.","journal-title":"N Engl J Med"},{"key":"2182_CR11","unstructured":"Who gets ALS? ALS Association website. https:\/\/www.als.org\/understanding-als\/who-gets-als. Accessed 28 Oct 2020."},{"issue":"2","key":"2182_CR12","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1056\/NEJMra1603471","volume":"377","author":"RH Brown","year":"2017","unstructured":"Brown RH, Al-Chalabi A. Amyotrophic lateral sclerosis. N Engl J Med. 2017;377(2):162\u201372.","journal-title":"N Engl J Med"},{"key":"2182_CR13","unstructured":"RADICAVA (edaravone). US prescribing information. Mitsubishi Tanabe Pharma America, Inc."},{"key":"2182_CR14","unstructured":"RILUTEK (riluzole). US prescribing information. Covis Pharmaceuticals, Inc."},{"issue":"1","key":"2182_CR15","first-page":"25","volume":"43","author":"MP Cruz","year":"2018","unstructured":"Cruz MP. Edaravone (Radicava): a novel neuroprotective agent for the treatment of amyotrophic lateral sclerosis. P T. 2018;43(1):25\u20138.","journal-title":"P T"},{"issue":"8","key":"2182_CR16","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1111\/jpc.12868","volume":"51","author":"EM Yiu","year":"2015","unstructured":"Yiu EM, Kornberg AJ. Duchenne muscular dystrophy. J Paediatr Child Health. 2015;51(8):759\u201364.","journal-title":"J Paediatr Child Health"},{"key":"2182_CR17","unstructured":"EXONDYS 51 (eteplirsen). US prescribing information. Sarepta Therapeutics, Inc."},{"key":"2182_CR18","doi-asserted-by":"publisher","first-page":"533","DOI":"10.2147\/DDDT.S97635","volume":"11","author":"KR Lim","year":"2017","unstructured":"Lim KR, Maruyama R, Yokota T. Eteplirsen in the treatment of Duchenne muscular dystrophy. Drug Des Dev Ther. 2017;11:533\u201345.","journal-title":"Drug Des Dev Ther"},{"issue":"1","key":"2182_CR19","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1080\/13696998.2019.1646263","volume":"23","author":"M Droege","year":"2020","unstructured":"Droege M, Sproule D, Arjunji R, Gauthier-Loiselle M, Cloutier M, Dabbous O. Economic burden of spinal muscular atrophy in the United States: a contemporary assessment. J Med Econ. 2020;23(1):70\u20139.","journal-title":"J Med Econ"},{"issue":"6","key":"2182_CR20","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1212\/WNL.0000000000000669","volume":"83","author":"E Landfeldt","year":"2014","unstructured":"Landfeldt E, Lindgren P, Bell CF, et al. The burden of Duchenne muscular dystrophy: an international, cross-sectional study. Neurology. 2014;83(6):529\u201336.","journal-title":"Neurology"},{"key":"2182_CR21","first-page":"1757","volume":"27","author":"KL Lenahan","year":"2021","unstructured":"Lenahan KL, Panzer AD, Gertler RM, Chambers JD. Use of prescriber requirements among US commercial health plans. J Manag Care Spec Pharm. 2021;27:1757\u201362.","journal-title":"J Manag Care Spec Pharm"},{"key":"2182_CR22","unstructured":"Orphan Drug Act, PL 97-414, 96 \u00a7 2049 (1983). https:\/\/www.govinfo.gov\/content\/pkg\/STATUTE-96\/pdf\/STATUTE-96-Pg2049.pdf. Accessed 21 Jan 2022."},{"issue":"1","key":"2182_CR23","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s13063-017-1870-2","volume":"18","author":"C Heneghan","year":"2017","unstructured":"Heneghan C, Goldacre B, Mahtani KR. Why clinical trial outcomes fail to translate into benefits for patients. Trials. 2017;18(1):122.","journal-title":"Trials"},{"key":"2182_CR24","unstructured":"Hammersmith Functional Motor Scale Expanded for SMA (HFMSE). March 29, 2019. http:\/\/columbiasma.org\/docs\/HFMSE_2019_Manual.pdf. Accessed 28 Oct 2020."},{"issue":"1","key":"2182_CR25","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s12883-017-0853-y","volume":"17","author":"S McGraw","year":"2017","unstructured":"McGraw S, Qian Y, Henne J, Jarecki J, Hobby K, Yeh WS. A qualitative study of perceptions of meaningful change in spinal muscular atrophy. BMC Neurol. 2017;17(1):68.","journal-title":"BMC Neurol"},{"issue":"5","key":"2182_CR26","doi-asserted-by":"publisher","first-page":"e5268","DOI":"10.1371\/journal.pone.0005268","volume":"4","author":"KJ Swoboda","year":"2009","unstructured":"Swoboda KJ, Scott CB, Reyna SP, et al. Phase II open label study of valproic acid in spinal muscular atrophy. PLoS One. 2009;4(5):e5268.","journal-title":"PLoS One"},{"issue":"11","key":"2182_CR27","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1377\/hlthaff.2019.00201","volume":"38","author":"JD Chambers","year":"2019","unstructured":"Chambers JD, Panzer AD, Pope EF, Graff JS, Neumann PJ. Little consistency in evidence cited by commercial plans for specialty drug coverage. Health Aff (Millwood). 2019;38(11):1882\u20136.","journal-title":"Health Aff (Millwood)"},{"issue":"10","key":"2182_CR28","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1002\/pds.4992","volume":"29","author":"AD Panzer","year":"2020","unstructured":"Panzer AD, Margaretos NM, Lai RC, Enright DE, Chambers JD. What types of real-world evidence studies do U.S. commercial health plans cite in their specialty drug coverage decisions? Pharmacoepidemiol Drug Saf. 2020;29(10):1307\u201311.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"3","key":"2182_CR29","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1038\/s41436-018-0086-5","volume":"21","author":"RR Howell","year":"2019","unstructured":"Howell RR, Zuchner S. MOVR-NeuroMuscular ObserVational Research, a unified data hub for neuromuscular diseases. Genet Med. 2019;21(3):536\u20138.","journal-title":"Genet Med"},{"issue":"2","key":"2182_CR30","doi-asserted-by":"publisher","first-page":"145","DOI":"10.3233\/JND-190451","volume":"7","author":"RS Finkel","year":"2020","unstructured":"Finkel RS, Day JW, De Vivo DC, et al. RESTORE: a prospective multinational registry of patients with genetically confirmed spinal muscular atrophy\u2014rationale and study design. J Neuromuscul Dis. 2020;7(2):145\u201352.","journal-title":"J Neuromuscul Dis"},{"key":"2182_CR31","unstructured":"Cure SMA Newborn Screening Registry. Cure SMA. https:\/\/www.curesma.org\/nbsr-sep2019\/. Accessed 27 Aug 2020."},{"issue":"12","key":"2182_CR32","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1377\/hlthaff.2010.1147","volume":"30","author":"PJ Neumann","year":"2011","unstructured":"Neumann PJ, Chambers JD, Simon F, Meckley LM. Risk-sharing arrangements that link payment for drugs to health outcomes are proving hard to implement. Health Aff (Millwood). 2011;30(12):2329\u201337.","journal-title":"Health Aff (Millwood)"},{"issue":"3","key":"2182_CR33","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.healthpol.2010.02.005","volume":"96","author":"JJ Carlson","year":"2010","unstructured":"Carlson JJ, Sullivan SD, Garrison LP, Neumann PJ, Veenstra DL. Linking payment to health outcomes: a taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers. Health Policy. 2010;96(3):179\u201390.","journal-title":"Health Policy"},{"key":"2182_CR34","unstructured":"Seeley E, Kesselheim AS. Outcomes-based pharmaceutical contracts: an answer to high U.S. drug spending? 2017. https:\/\/www.commonwealthfund.org\/publications\/issue-briefs\/2017\/sep\/outcomes-based-pharmaceutical-contracts-answer-high-us-drug. Accessed 27 Aug 2020."},{"issue":"3","key":"2182_CR35","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.healthpol.2017.11.012","volume":"122","author":"E Hanna","year":"2018","unstructured":"Hanna E, Toumi M, Dussart C, et al. Funding breakthrough therapies: a systematic review and recommendation. Health Policy. 2018;122(3):217\u201329.","journal-title":"Health Policy"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-022-02182-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-022-02182-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-022-02182-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,5]],"date-time":"2022-02-05T11:14:26Z","timestamp":1644059666000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-022-02182-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,5]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2182"],"URL":"https:\/\/doi.org\/10.1186\/s13023-022-02182-3","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,5]]},"assertion":[{"value":"8 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Institutional review board (IRB) approval was waived for this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"KB and NE are current employees of Genentech, Inc. and shareholders of Roche. NM and JC have no competing interests to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"36"}}